WASHINGTON — The United States Food and Drug Administration (FDA) has approved pimicotinib, sold under the brand name Pimjetmi, for adults living with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgery could make their movement worse or cause serious harm, the agency announced on 10 November 2026. The decision gives doctors and patients a new oral treatment option for a rare joint tumor that can cause lasting pain, swelling and stiffness, and that often comes back after an operation. Pimicotinib is a kinase inhibitor taken as a 50-milligram tablet once a day, with or without food, according to the FDA. It works by blocking a protein called colony-stimulating factor-1 receptor, or CSF-1R, whose signaling drives the growth of the tumor cells. The medicine was developed by Abbisko Therapeutics, where it carries the code name ABSK021, and it is marketed in the United States by EMD Serono. China approved the drug in December 2025, the first approval anywhere in the world, ...